Genmab — Juni 2019

[Bella1]

En grøn dag truer....

[E_L]

@ 07:21 we are getting some early data on the SC DARA + CyBorD AL amyloidosis.trial. early, but ORR 96% , VGPR 82%; 36% CR
https://learningcenter.ehaweb.org/eha/2019/24th/267458/raymond.l.comenzo.subcutaneous.daratumumab.2B.cyclophosphamide.bortezomib.and.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Ddaratumumab%2Bamyloidosis

[E_L]

also https://learningcenter.ehaweb.org/eha/2019/24th/267016/yael.c.cohen.real.world.data.on.the.efficacy.and.safety.of.daratumumab.for.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Ddaratumumab%2Bamyloidosis

[Tandfeen-2]

Thanks EL. Funny that the date on the paper is june 15 2019

[E_L]

that is when it will be presented at EHA conference

[Solsen]

Enig StockBull…

[Tandfeen-2]

Pyha, vinden blæser ikke vores vej

[Solsen]

The link is empty from EHA ?

[bibob]

Vinden har det med at vende.

[Solsen]

This is significant news I belive !

[Solsen]

Var det ikke 12000 pts i denne gruppe. Ninlaro fra Takeda stoppede netop en fase 3 i denne indikation i går https://finance.yahoo.com/news/takeda-provides-tourmaline-al1-phase-203000255.html

[Solsen]

More $bn to Dara

[bibob]

Lets hope so.

[E_L]

can you not get the EHA abstracts from those links?

[Solsen]

Yes on my Ipad not my PC. Thanks !

[E_L]

ok. saw these tweets earlier this week from a big kidney conference in the Uk, assuming they are using the same data https://twitter.com/jeremyblevy/status/1135951536822128640 https://twitter.com/jeremyblevy/status/1135953801477873665

[bibob]

" the new backbone agent " . Strong Words. I like them

[Bulder]

When do we expect top line data from Andromeda? Early next year?

[E_L]

i am just reading this article , which seems to think Feb 2020 https://www.evaluate.com/vantage/articles/analysis/takeda-casts-doubt-remaining-approach-amyloidosis

[Bulder]

Tx. it's a bit strange that ixazomib doesn't work in amy as bortezomib apparantly works well with dara. Maybe some kind of synergi (again).